Navigation Links
Roches Arthritis Drug Successful in III Stage Trail

Roche Holding AG says that arthritis drug Actemra has proved successful in a phase III clinical study. Actemra helps relieve symptoms of rheumatoid arthritis in difficult-to-treat patients in a clinical study thus bringing it closer to regulatory approval.

The Radiate study was conducted over 24 weeks with 498 patients with difficult-to-treat RA. Actemra was given in combination with a standard treatment called methotrexate in patients who had an inadequate response to a relatively new type of drugs known as anti-tumor necrosis factor therapy, or anti-TNFs. The treatment showed a significant improvement in disease signs and symptoms.

Biologic Actemra (tocilizumab), a humanized monoclonal antibody works by a different mechanism than today's rheumatoid arthritis treatments. Actema is the first biologic to inhibit the interleukin-6, or Il-6, receptor. IL-6 is considered an important mediator of the acute inflammatory response.

Sufferers of rheumatoid arthritis, or RA, begin to experience progressive joint damage early in the disease. The disease differs from what is popularly known as arthritis, typically associated with age-related joint pain; RA is a far more serious inflammatory disease that leads to destruction of cartilage and bone, and can lead to disability.

Roche plans to file Actemra, developed by Japanese pharmaceutical company Chugai Pharmaceutical Co. which Roche controls, for regulatory approval in Europe and the U.S. by the end of 2007.

This is the third of five international late-stage trials that are investigating Actemra's efficacy and safety. Roche plans to release results from one more this year, while data from the fifth study will become available at a later date.


'"/>




Page: 1

Related medicine news :

1. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
2. Another ray of hope for Arthritis Sufferers
3. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
4. B Vitamin protects and lowers toxicity of Arthritis Drug
5. FDA Approves New Arthritis Drug, Bextra
6. Risk Of Developing Arthritis
7. Arthritis Drug May Cause Liver Damage
8. Arthritis drug can prolong life
9. New treatment for Rheumatoid Arthritis
10. Important cause of Arthritis
11. Personality Impacts Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Roches Arthritis Drug Successful III Stage Trail

(Date:7/1/2015)... ... July 01, 2015 , ... Northbound Treatment Services announced today ... Relations. , Emily originally entered the behavioral healthcare industry as an academic ... academic curriculum for clients to engage in their educational journey while in treatment. ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... dedicated to the global distribution and marketing of a number of nutritional and ... when it attended the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... different philosophies and approaches to case management, placement, sober companionship and delivery to ... and approaches to working with and transporting clients with anxiety, ADHD, autism spectrum ...
(Date:7/1/2015)... ... ... The Thule Atmos X4 offers protection with minimal bulk. At the Thule ... rigorous standards. Due to its Bi-ComponentArmor and ShockStop corners, it passed Thule’s 2 meter ... , The Thule Atmos X4 has also been designed with function in mind. ...
(Date:7/1/2015)... (PRWEB) , ... July 01, ... ... in the communities of southeast Alabama, southwest Georgia and the Florida Panhandle, ... TelmedIQ as its primary secure text messaging and clinical communications workflow solution ...
Breaking Medicine News(10 mins):Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2
... 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ... will provide a corporate,overview at the upcoming Collins Stewart ... July 8, 2008 in New York, NY., Interested ... visiting,the Sunesis website at http://ir.sunesis.com . A replay ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... 2 The Michigan Attorney General announced,on July 2 ... Shield of,Michigan challenging a capital transaction between BCBSM and ... position that BCBSM is not,authorized by Public Act 350 ... Accident Fund obtained prior regulatory approval for the,transaction. BCBSM ...
... has spread to distant sites has a poor prognosis, but ... slow disease progression in some patients, a research team led ... Cancer Center reports in the July 3rd edition of ... drug, motesanib diphosphate, is a VEGF inhibitor, a biologic agent ...
... 2 A Miami resident was,sentenced to 130 months ... the,Medicare program, Acting Assistant Attorney General Matthew Friedrich of,the ... the Southern,District of Florida announced today., Gustavo Smith, ... for,the Southern District of Florida by Judge Marcia G. ...
... Hanger Orthopedic,Group, Inc. (NYSE: HGR ) ... Services revised its outlook for Hanger Orthopedic Group, ... corporate credit,rating at "B." "The outlook revision reflects ... improved financial risk profile," said,Standard & Poor,s credit ...
Cached Medicine News:Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2
(Date:7/1/2015)... The Haselmeier Group has decided to reinforce ... has been nominated by the Board of Directors ... (CEO) of the Haselmeier Group. This nomination is ... brings more than 20 years of experience in the ... management positions, the last being Managing Director and Vice ...
(Date:6/30/2015)... -- Inventor of ProTide technology ...   NuCana, a clinical stage biopharmaceutical company ... portfolio of novel anti-cancer medicines, today announced the appointment ... Officer. Professor McGuigan was the original inventor ... Medicinal Chemistry at the Cardiff School of Pharmacy and ...
(Date:6/30/2015)... Ansell, a global leader in protection solutions, ... Ansell Cares ® H.E.R.O. Service Award ... organised in partnership with the European Operating Room Nurses ... and quality in patient care, and present an in-depth ... taking place today in the winners, respective hospitals in ...
Breaking Medicine Technology:Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3Ansell Announces European O.R. Nurse Hero Award Winners 2Ansell Announces European O.R. Nurse Hero Award Winners 3
... SAN DIEGO, May 5, 2011 /PRNewswire/ -- Halozyme ... developing and commercializing products targeting the extracellular matrix , ... of America Merrill Lynch Health Care Conference in Las Vegas. ... PDT (2:10 p.m. EDT). To listen to the live webcast ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... 31, 2011.  Savient ended the quarter with $268.0 million in ... December 31, 2010, primarily due to the issuance and sale ... the first quarter of 2011, the Company had a net ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
Medicine Products: